EXD2: A new regulator of mitochondrial translation and potential target for cancer therapy. (4th May 2018)

• Record Type: Journal Article
• Authors: Stracker, Travis H.
• Is Part Of: Molecular & cellular oncology. Volume 5:Number 3(2018)
• Publication Date: 2018-05-04
• Subjects: EXD2 -- mitochondria -- metabolic reprogramming -- metformin -- cancer metabolism -- translation -- glutamine -- Biology of malignant cells -- Cancer stem cells -- Mode of action of anticancer agents -- Tumor metabolism; Tumors -- Periodicals; Neoplasms; Periodicals; 616.99
• DOI: 10.1080/23723556.2018.1445943
• Languages: English
• ISSNs: 2372-3556

Abstract

ABSTRACT: In recent work we identified Exonuclease 3′−5′ domain-containing protein 2 (EXD2) as an RNase required for efficient mitochondrial translation. Here I describe in brief the cellular phenotypes caused by EXD2 deficiency and make the case that EXD2 inhibitors could be valuable agents for cancer therapy.